Rockville, Md. (July 18, 2023) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today announced the United States Patent and Trademark Office (USPTO) issued a patent, entitled Thrombosomes as an Antiplatelet Reversal Agent (Patent US 11,701,388 B2 ('388 Patent)) covering the application of our Freeze-Dried Platelet-Derived Hemostat Technology (FPH) to restore hemostasis on patients bleeding as a result of all classes of antiplatelet antagonists. FPH, also known as Thrombosomes®, creates a novel, shelf-stable hemostatic agent currently in Phase II clinical trials.
According to Keith Moskowitz, VP of Discovery Research, “this is the second issued patent in the US for Cellphire Therapeutics’ FPH core technology, allowing expanded claims and coverage through 2042. The patent covers the use of FPH for patients on Antiplatelet Therapy, a significant unmet clinical need with over 10 million patients in the US on such therapies. This demonstrates Cellphire Therapeutics’ product insight and innovation.”
"This is another important milestone for the company on the road to achieving our mission of saving lives with our cellular therapeutics,” indicated Mike Gaffney, Cellphire Therapeutics CEO. “We appreciate and thank our collaborators, BARDA and other federal funding agencies, and our team for helping us realize this achievement.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational technology is FPH/Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications, including unique Orphan populations, perioperative bleeding, and intracranial hemorrhage unmet clinical needs. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, Department of Health and Human Services, under contract number HHSO100201300021C.
VP, Business Operations